Bausch + Lomb (NYSE:BLCO) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Bausch + Lomb (NYSE:BLCO) announced its quarterly earnings data on Wednesday. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.13, FiscalAI reports. The company had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.37 billion. During the same period in the prior year, the firm posted $0.18 earnings per share. The business’s quarterly revenue was up 7.3% compared to the same quarter last year.

Here are the key takeaways from Bausch + Lomb’s conference call:

• Strong third-quarter results: Constant-currency revenue rose 8% to $1.375 billion, adjusted EBITDA increased 34% to $325 million, and adjusted EBITDA margin expanded 460 basis points to 23.6%.
• Management raised 2026 guidance for the third time, increasing revenue guidance to $5.45 billion–$5.55 billion and adjusted EBITDA guidance to $1.09 billion–$1.14 billion, implying approximately 20.3% full-year EBITDA margin.
• Growth was broad-based across all segments, led by Pharmaceuticals at 11%, Surgical at 9%, and Vision Care at 6%; key products included MIEBO, LUMIFY, Daily SiHy contact lenses, and premium IOLs.
• Cash generation strengthened, with $233 million of operating cash flow and $178 million of free cash flow, reducing net leverage to 4.1 times from 5.7 times a year earlier and keeping the company on track toward its 3.5-times target.
• Tom Appio is serving as interim CEO following a mutually agreed leadership transition. He emphasized operational efficiency, disciplined capital allocation, debt reduction, and advancing the innovation pipeline, while providing limited detail on the reasons for the change.

Bausch + Lomb Stock Up 9.4%

Bausch + Lomb stock traded up $1.66 during mid-day trading on Wednesday, hitting $19.28. The company’s stock had a trading volume of 1,167,339 shares, compared to its average volume of 437,980. The stock’s fifty day moving average price is $17.18 and its two-hundred day moving average price is $16.64. The stock has a market capitalization of $6.89 billion, a P/E ratio of -40.06 and a beta of 0.56. Bausch + Lomb has a twelve month low of $14.44 and a twelve month high of $19.44.

More Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Adjusted EPS significantly beat estimates. Bausch + Lomb reported third-quarter adjusted earnings of $0.34 per share, compared with consensus estimates ranging from $0.21 to $0.22 and $0.18 in the prior-year quarter. Bausch + Lomb Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Revenue also topped expectations. Quarterly revenue reached approximately $1.38 billion, narrowly exceeding the $1.37 billion consensus forecast and increasing about 7% to 7.3% year over year. Bausch + Lomb Reports Q3 Revenue Above Estimate
• Positive Sentiment: Management raised its 2026 outlook. The improved forecast, together with strong third-quarter growth in the company’s eye-care business, signals greater confidence in operating performance and supports the bullish market reaction. Bausch + Lomb Lifts 2026 Outlook
• Neutral Sentiment: The earnings reaction reflects a concentrated catalyst. The available reports largely repeat the same quarterly results, so investors may now focus on the details of the updated full-year guidance and management’s conference call for evidence that the stronger performance can continue. Bausch + Lomb Swings to Profit and Lifts FY26 Guidance

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BLCO. Evercore set a $17.00 target price on shares of Bausch + Lomb in a research note on Monday, July 6th. Weiss Ratings raised Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of Bausch + Lomb in a report on Friday, August 28th. Citigroup increased their price target on Bausch + Lomb from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, Barclays upgraded shares of Bausch + Lomb to a “strong-buy” rating in a research note on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $19.46.

Insider Activity at Bausch + Lomb

In other news, CAO Frederick Munsch sold 52,900 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $16.78, for a total value of $887,662.00. Following the transaction, the chief accounting officer owned 45,831 shares in the company, valued at $769,044.18. This represents a 53.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $16.50, for a total transaction of $206,250.00. Following the transaction, the director owned 69,792 shares in the company, valued at approximately $1,151,568. This represents a 15.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 71,459 shares of company stock worth $1,194,370. Corporate insiders own 1.45% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.